ENXTPA:SANPharmaceuticals
Sanofi’s Dupixent Win In Children May Reinforce Undervalued Growth Story
Sanofi (ENXTPA:SAN) received US FDA approval for Dupixent in children aged 2 to 11 years with chronic spontaneous urticaria.
The decision makes Dupixent the first biologic medicine cleared in the US for this indication in young children.
The approval addresses a significant unmet medical need for pediatric patients with persistent hives and itch.
For Sanofi, Dupixent sits at the core of its immunology franchise, targeting type 2 inflammation driven diseases. By extending use into younger...